TY - JOUR
T1 - Thyroid Dysfunction and Thyroid Cancer in Childhood Cancer Survivors
T2 - Prevalence, Surveillance and Management
AU - Lebbink, Chantal A
AU - Waguespack, Steven G
AU - van Santen, Hanneke M
N1 - Publisher Copyright:
© 2021 S. Karger AG. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Childhood cancer survivors (CCS) are at increased risk of developing thyroid disorders during follow-up. Radiation therapy to a field that includes the thyroid gland and 131I-meta-iodobenzylguanidine (131I-MIBG) treatment are the main risk factors for thyroid sequelae, which include decreased thyroid function, hyperthyroidism, thyroid nodules, and differentiated thyroid cancer, specifically papillary thyroid carcinoma. In addition, treatment with anti-neoplastic drugs or immunotherapy may result in thyroid dysfunction. Central hypothyroidism may be seen in CCS after cranial radiotherapy, after immunotherapy, or secondary to a brain tumor that involves the hypothalamic-pituitary region and will be discussed elsewhere in this series. In this chapter, the prevalence, risk factors, surveillance, and management of primary hypothyroidism, hyperthyroidism, thyroid nodules, and differentiated thyroid carcinoma in CCS are discussed.
AB - Childhood cancer survivors (CCS) are at increased risk of developing thyroid disorders during follow-up. Radiation therapy to a field that includes the thyroid gland and 131I-meta-iodobenzylguanidine (131I-MIBG) treatment are the main risk factors for thyroid sequelae, which include decreased thyroid function, hyperthyroidism, thyroid nodules, and differentiated thyroid cancer, specifically papillary thyroid carcinoma. In addition, treatment with anti-neoplastic drugs or immunotherapy may result in thyroid dysfunction. Central hypothyroidism may be seen in CCS after cranial radiotherapy, after immunotherapy, or secondary to a brain tumor that involves the hypothalamic-pituitary region and will be discussed elsewhere in this series. In this chapter, the prevalence, risk factors, surveillance, and management of primary hypothyroidism, hyperthyroidism, thyroid nodules, and differentiated thyroid carcinoma in CCS are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85102627410&partnerID=8YFLogxK
U2 - 10.1159/000513805
DO - 10.1159/000513805
M3 - Article
C2 - 33690237
SN - 0301-3073
VL - 54
SP - 140
EP - 153
JO - Frontiers of hormone research
JF - Frontiers of hormone research
ER -